AMPK–SQSTM1 Feedback Under Metabolic Stress

Metabolic stress is not simply a consequence of nutrient deprivation; in tumors, it is a selective pressure that reshapes signaling, lysosomal function, redox balance, and growth. The reference study, published in Autophagy in 2024, examines how these responses are integrated through SQSTM1/p62, AMPK, and NFE2L2/NRF2. Its central contribution is the identification of a self-reinforcing AMPK–SQSTM1 circuit that enables cells to activate both energy conservation and antioxidant defense.

The findings are particularly relevant to non-small cell lung cancer (NSCLC) biology, where loss of STK11/LKB1 weakens canonical AMPK activation and co-occurring KEAP1 alterations can constitutively activate NFE2L2/NRF2. Rather than treating these pathways as independent compensatory systems, the study proposes that metabolic stress connects them through SQSTM1 and TAK1.

Study Background and Research Question

Glucose and nutrient limitation reduce metabolic fluxes that support ATP synthesis and NADPH production. The resulting energy deficit increases AMP:ATP or ADP:ATP ratios, while impaired mitochondrial respiration and reduced antioxidant capacity promote reactive oxygen species (ROS) accumulation. Energy and oxidative stress therefore amplify one another. STK11/LKB1 normally activates AMPK under these conditions, helping cells limit ATP consumption, preserve NADPH, and maintain redox homeostasis.

A second stress-adaptation route is the KEAP1–NFE2L2/NRF2 axis. When KEAP1 is removed or functionally disabled, NFE2L2/NRF2 accumulates and induces antioxidant and detoxification programs. SQSTM1/p62 is known to interact with KEAP1 and can promote its autophagic degradation, but the extent to which p62 also coordinates AMPK signaling remained unresolved.

The reference study asks whether metabolic stress produces reciprocal regulation between AMPK and SQSTM1, and whether this relationship can explain simultaneous activation of AMPK and NFE2L2/NRF2. It also investigates how lysosomal pH, calcium release, ROS, and the kinase MAP3K7/TAK1 contribute to the circuit. The authors’ interpretation is detailed in the reference study.

Key Innovation from the Reference Study

The major innovation is the double-positive feedback model. Metabolic stress increases SQSTM1 expression and phosphorylation, while STK11–AMPK activity is itself required for that SQSTM1 response. In other words, AMPK does not merely respond to p62 activity, and p62 does not act only downstream of AMPK. The two systems reinforce one another, creating a sustained adaptation rather than a transient stress response.

SQSTM1 produces two complementary outputs. First, it promotes macroautophagic degradation of KEAP1, releasing NFE2L2/NRF2 to activate antioxidant gene expression. Second, it facilitates formation of the AXIN–STK11–AMPK complex on the lysosomal membrane, supporting AMPK activation at a signaling platform that senses lysosomal and metabolic status. This arrangement provides a mechanistic explanation for how one stress-responsive adaptor can coordinate redox protection with energy management.

The study further places lysosomal deacidification upstream of SQSTM1 induction. Low glucose metabolism and AMPK-dependent proton reduction alter lysosomal acidity, leading to PPP2/PP2A-dependent dephosphorylation of TFEB and TFE3. These transcription factors then contribute to increased SQSTM1 expression. In parallel, ROS and pH-dependent lysosomal calcium release activate MAP3K7/TAK1, which increases SQSTM1 phosphorylation. The reported phosphorylation sites, S24 and S226, are functionally important for both AMPK and NFE2L2 activation.

This model links several processes that are often studied separately: nutrient sensing, lysosomal signaling, autophagy, transcriptional control, kinase activation, and antioxidant defense. It also offers a possible explanation for the co-occurrence of STK11 and KEAP1 alterations in tumors: disruption of one stress-adaptation route may increase the selective value of strengthening another.

Methods and Experimental Design Insights

The experimental logic combines stress induction, molecular perturbation, pathway readouts, and functional validation. Metabolic stress was modeled through low-nutrient or low-glucose conditions, allowing the investigators to follow changes in AMPK activity, SQSTM1 abundance and phosphorylation, KEAP1 turnover, NFE2L2/NRF2 activation, ROS, and lysosomal behavior. Cell systems included models relevant to metabolic adaptation, with mouse embryonic fibroblast and NSCLC-related contexts represented in the study.

A key strength is the use of interventions that distinguish correlation from causality. Lysosomal acidification was perturbed with agents such as bafilomycin A1 or concanamycin A, while ROS dependence was examined using antioxidant intervention. The study also tested whether adding lactic acid-derived protons could reverse the effects of metabolic stress. The observation that lactic acid abrogated the stress-induced response supports a role for proton availability and lysosomal pH rather than nutrient depletion alone.

Protein-level assays were used to assess SQSTM1 phosphorylation, AMPK activation, KEAP1 abundance, and NFE2L2/NRF2 signaling. Interaction-focused experiments examined formation of the AXIN–STK11–AMPK complex, while lysosomal measurements addressed acidification and calcium release. These layered measurements are important because a change in total p62 abundance does not, by itself, establish whether p62 is acting through autophagy, transcriptional regulation, kinase recruitment, or phosphorylation-dependent signaling.

For researchers adapting this design, the main lesson is to use orthogonal controls. A low-glucose condition should be paired with measurements of cellular stress and lysosomal state; a pathway inhibitor should be interpreted alongside genetic or biochemical evidence; and antioxidant rescue should not be treated as proof of a single ROS source. The reference study’s design is therefore more informative than a simple endpoint assay because it maps the directionality of the feedback loop.

Protocol Parameters

The paper provides a mechanistic framework rather than a universal protocol. The following parameters distinguish study-aligned observations from practical workflow suggestions:

• Metabolic-stress condition: Use low-nutrient or low-glucose culture as the study-aligned trigger for metabolic and lysosomal stress; optimize the severity and exposure time for the chosen cell system rather than transferring an unvalidated condition directly.
• Primary molecular readouts: Measure SQSTM1 expression, SQSTM1 phosphorylation at S24 and S226, AMPK activation, KEAP1 abundance, and NFE2L2/NRF2 pathway output in the same experiment.
• Lysosomal controls: Include lysosomal acidification and calcium-related measurements when testing the proposed pH-dependent mechanism. Acidification perturbation should be described as a mechanistic control, not as a substitute for nutrient stress.
• Redox controls: Use an antioxidant rescue condition, such as the study’s NAC-based approach, to test whether ROS contributes to TAK1 activation and p62 phosphorylation.
• TAK1 perturbation: A selective TAK1 inhibitor can be added as an orthogonal test of the ROS- and lysosomal calcium-linked branch, but dose, exposure time, and target engagement should be established independently in each model.

Core Findings and Why They Matter

Several findings define the proposed mechanism. Metabolic stress increased SQSTM1 expression and phosphorylation, and this response depended on STK11–AMPK activity. SQSTM1 then activated NFE2L2/NRF2 by promoting KEAP1 degradation and supported AMPK activation by helping organize the AXIN–STK11–AMPK complex at lysosomes.

The authors also connect AMPK to the transcriptional control of SQSTM1. Metabolic stress and AMPK-dependent proton reduction caused lysosomal deacidification, which promoted PP2A-dependent dephosphorylation of TFEB and TFE3. This transcriptional route increased SQSTM1 expression, closing one side of the feedback loop.

The second side involved MAP3K7/TAK1. ROS and pH-dependent secretion of lysosomal calcium activated TAK1, which increased SQSTM1 phosphorylation. Phosphorylation at S24 and S226 was not merely associated with pathway activation; it was required for effective activation of both AMPK and NFE2L2/NRF2. This places TAK1 at an important control point between lysosomal stress and the p62-centered adaptive response.

Functionally, the circuit strengthens antioxidant defense and supports tumor-cell adaptation under metabolic stress. The lactic acid result is also notable because it suggests that the tumor microenvironment can modulate this response through extracellular proton availability. A highly glycolytic environment may therefore influence whether nutrient stress produces the lysosomal and signaling changes described in the study.

For inflammation researchers, the TAK1 observation is mechanistically relevant but should be interpreted carefully. TAK1 is a broader stress and cytokine-responsive kinase, whereas the paper’s primary biological question concerns metabolic adaptation and tumor growth. A TAK1 inhibitor can help test whether TAK1-dependent SQSTM1 phosphorylation is necessary in a given stress model, but inhibition alone cannot reproduce the full AMPK–SQSTM1 feedback circuit.

Comparison with Existing Internal Articles

The internal article AMPK–SQSTM1 Feedback Enhances Antioxidant Defense in Metabolic Stress provides a concise overview of the same conceptual advance: reciprocal AMPK and SQSTM1 activation produces coordinated NFE2L2/NRF2 and energy-stress signaling. The present analysis adds the mechanistic detail that makes the model experimentally testable, especially the roles of lysosomal deacidification, PP2A, TFEB/TFE3, TAK1, and the S24/S226 phosphorylation sites.

A second related resource, (5Z)-7-Oxozeaenol: Illuminating TAK1–SQSTM1 Crosstalk in Inflammation, approaches the biology from a TAK1-perturbation perspective. It is useful as a conceptual bridge for designing kinase-inhibition experiments, but it should not be treated as evidence that the reference study used that compound or that inflammatory signaling and metabolic adaptation are interchangeable experimental settings.

Limitations and Transferability

The proposed feedback loop is compelling, but several boundaries remain. First, metabolic stress is highly dependent on cell lineage, nutrient composition, culture density, oxygenation, and baseline STK11 or KEAP1 status. A response observed in one NSCLC model may not be quantitatively reproduced in another. Second, pharmacological manipulation of lysosomes, ROS, or TAK1 can have off-target or pathway-wide effects, making genetic rescue and target-engagement controls important.

Third, p62 has functions beyond KEAP1 degradation and AMPK recruitment, including roles in selective autophagy and protein aggregation. The study identifies S24 and S226 as critical in this setting, but the broader context-dependent consequences of these modifications require further work. Finally, the evidence supports a mechanistic explanation for tumor adaptation; it does not by itself establish that disrupting the loop will be safe or effective in patients.

Why this cross-domain matters, maturity, and limitations

TAK1 is also studied in cytokine-driven inflammation, where it regulates NF-κB and JNK/p38 MAPK signaling. This creates a useful cross-domain opportunity: a TAK1 perturbation can test whether the kinase-dependent branch of SQSTM1 regulation is conserved across stress contexts. The maturity of this bridge is mechanistic rather than translational. The reference study supports TAK1 involvement in metabolic-stress-induced p62 phosphorylation, while product information supports use of a selective TAK1 inhibitor in inflammatory signaling assays. These sources justify comparative experiments, but they do not establish that an inflammation model compound will fully predict tumor-cell metabolic adaptation.

Research Support Resources

For experiments focused on the TAK1-dependent branch, researchers can use (5Z)-7-Oxozeaenol (SKU B7443) as a selective TAK1 inhibitor and compare its effects with the reference study’s AMPK, lysosomal, ROS, and SQSTM1 readouts. The linked product information describes it as an inhibitor of NF-κB signaling and a JNK/p38 MAPK pathway inhibitor, with downstream suppression of cyclooxygenase-2 (COX-2) production; these properties make it a useful inflammation model compound for complementary validation, not a replacement for the paper’s metabolic-stress experiments.